Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$79.33 USD

79.33
5,728,877

-2.48 (-3.03%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $79.34 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

What's in the Cards for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) product purchases and introductions in the Rx segment are expected to boost sales.

    Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down

    Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.

      Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval

      Pfizer (PFE) reports strong second-quarter results. European Commission approves Pfizer and Bristol-Myers' (BMY) medicines.

        TESARO (TSRO) Misses Earnings and Revenue Estimates in Q2

        TESARO (TSRO) misses estimates for both earnings and revenues in the second quarter but beats on revenues. Zejula sales increase.

          Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT

          Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.

            Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod

            Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.

              Merck (MRK) Q2 Earnings & Sales Top on Keytruda Strength

              Merck (MRK) beat estimates for both earnings and sales in second-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.

                AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up

                AstraZeneca (AZN) beats earnings and sales estimates in the second quarter on the back of strong new product sales and maintains previously issued outlook for 2018.

                  AstraZeneca Sells Atacand's European Rights to Cheplapharm

                  AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.

                    Ironwood Begins New Phase III Study to Expand Linzess Label

                    Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.

                      Novartis Looks to Exit Antibacterial, Antiviral Program

                      Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.

                        Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

                        Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

                          Biogen's Alzheimer Disease Candidate Succeeds in Phase II

                          Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.

                            Clovis Gets EU Acceptance for Rubraca Label Expansion Filing

                            Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.

                              Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs

                              Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.

                                AstraZeneca's Two New Cancer Drugs Get Approval in Japan

                                AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication and Imfinzi for an early-stage lung cancer indication.

                                  Swarup Gupta headshot

                                  Dow 30 Stock Roundup: Nike, Walgreens Earnings Impress

                                  The Dow endured a turbulent week, marked by lingering trade tensions.

                                    AstraZeneca/Merck's Lynparza Betters Survival in Phase III

                                    AstraZeneca (AZN) and Merck's (MRK) Lynparza significantly delays disease progression in a late-stage study evaluating it for the first-line treatment of advanced ovarian cancer.

                                      Pfizer's Breast Cancer Drug Misses Overall Survival in Study

                                      Pfizer (PFE) announces that in the phase III PALOMA-3 study, the combination of Ibrance and Faslodex failed to improve overall survival in women with breast cancer compared with Faslodex and placebo.

                                        Merrimack Crashes as Phase II Pancreatic Cancer Study Fails

                                        Merrimack (MACK) plunges, following the announcement of failure of the CARRIE phase II study on pipeline candidate, MM-141, for the treatment of metastatic pancreatic cancer.

                                          Merck (MRK) Presents New Data from Januvia Diabetes Studies

                                          Merck (MRK) produces new data from two studies on type II diabetes medicine Januvia (sitagliptin), which supports the drug's clinical profile.

                                            Ironwood Initiates Phase III Studies on Reflux Candidate

                                            Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.

                                              Merck (MRK) Stock Up So Far This Year on Keytruda Strength

                                              Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.

                                                Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study

                                                Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.

                                                  Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

                                                  Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.